Ultragenyx Pharmaceutical (RARE) Cash & Equivalents (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Cash & Equivalents data on file, last reported at $175.0 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $175.0 million, up 37.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $175.0 million (up 37.8% YoY), and the FY2025 annual result was $421.0 million, up 141.95% from the prior year.
• Cash & Equivalents retreated to $175.0 million in Q1 2026 per RARE's latest filing, from $421.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $480.7 million in Q2 2024 and troughed at $72.6 million in Q3 2023.
• A 5-year average of $196.0 million and a median of $159.9 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents tumbled 81.47% in 2023, then jumped 371.0% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $132.9 million in 2022, then surged by 60.97% to $214.0 million in 2023, then decreased by 18.69% to $174.0 million in 2024, then soared by 141.95% to $421.0 million in 2025, then plunged by 58.43% to $175.0 million in 2026.
• Business Quant data shows RARE's Cash & Equivalents at $175.0 million in Q1 2026, $421.0 million in Q4 2025, and $202.5 million in Q3 2025.